Yvonne Tan, Svetlana Kavaklieva, Fiona Wood
No abstract text is available yet for this article.
April 9, 2021: Rheumatology
Jashmitha Rammanohar, Chen Zhang, Arlsan A Sidhu
No abstract text is available yet for this article.
April 9, 2021: Rheumatology
Matthias Papo, Chloé Friedrich, Laure Delaval, Hubert de Boysson, Jean-François Viallard, Claude Bachmeyer, Thomas Sené, Sébastien Humbert, Pierre Duffau, Anne Contis, Christian Agard, Bruno Gombert, Mathieu Puyade, Aurélie Foucher, Anne-Sophie Alary, François-Xavier Danlos, Alexis Régent, Luc Mouthon, Loïc Guillevin, Maxime Samson, Olivier Kosmider, Benjamin Terrier
OBJECTIVES: Giant cell arteritis (GCA) is a large vessel vasculitis for which triggering factors remain unknown. Clonal hematopoiesis (CH) was associated with atherosclerosis through the induction of inflammation in myeloid cells, and data suggest that CH expansion and inflammation may support each other to induce a proinflammatory loop. Our objective was to describe the impact of JAK2p.V617F-mutated myeloproliferative neoplasms (MPN) on GCA and to screen MPN-free patients for CH mutations...
April 9, 2021: Rheumatology
Michelle L M Mulder, Mark H Wenink, Johanna E Vriezekolk
OBJECTIVE: To assess sex differences in disease activity parameters and health-related quality of life in Psoriatic arthritis (PsA), and to assess whether determinants associated with not reaching treatment target differed between men and women. METHODS: Routine practice data of 855 PsA patients, who were all tightly monitored and treated, was used. Sex differences including, but not limited to, Psoriatic Arthritis Disease Activity Score (PASDAS), skin/nail disease, SF12-PCS/MCS, and inflammatory back pain (IBP) were assessed...
April 8, 2021: Rheumatology
Verena Schönau, Jessica Roth, Koray Tascilar, Giulia Corte, Bernhard Manger, Juergen Rech, Daniela Schmidt, Alexander Cavallaro, Michael Uder, Filippo Crescentini, Luigi Boiardi, Massimiliano Casali, Lucia Spaggiari, Elena Galli, Torsten Kuwert, Annibale Versari, Carlo Salvarani, Georg Schett, Francesco Muratore
OBJECTIVES: Efficacy evaluation of giant cell arteritis (GCA) treatment is primarily based on non-specific symptoms and laboratory markers. We aimed to assess the change in vascular inflammation in patients with large vessel (LV)-GCA under different treatments using [18F]FDG PET/CT. METHODS: Observational study on patients with new-onset, active LV-GCA starting treatment with either prednisolone monotherapy (PRED) or combination with methotrexate (MTX) or tocilizumab (TOC)...
April 8, 2021: Rheumatology
Sharan K Rai, Hyon K Choi, Eric C Sayre, J Antonio Aviña-Zubieta
No abstract text is available yet for this article.
April 7, 2021: Rheumatology
Hanene Lassoued Ferjani, Dorra Ben Nessib, Kaouther Maatallah, Wafa Hamdi
No abstract text is available yet for this article.
April 7, 2021: Rheumatology
Dennis McGonagle, Iain B McInnes, Atul Deodhar, Georg Schett, May Shawi, Shelly Kafka, Chetan S Karyekar, Alexa P Kollmeier, Elizabeth C Hsia, Xie L Xu, Shihong Sheng, Prasheen Agarwal, Bei Zhou, Christopher T Ritchlin, Proton Rahman, Philip J Mease
OBJECTIVE: To further characterize the effect of guselkumab, a selective interleukin-23p19-subunit inhibitor approved for psoriatic arthritis (PsA), on enthesitis and assess relationships between enthesitis resolution and patient status/outcomes. METHODS: Adults with active PsA despite standard therapies in the Phase-3 DISCOVER-1 and DISCOVER-2 studies were randomized 1:1:1 to guselkumab 100 mg every-4-weeks (Q4W); guselkumab 100 mg at Week0, Week4, Q8W; or placebo through Week20 followed by guselkumab 100 mg Q4W (Placebo→Q4W)...
April 6, 2021: Rheumatology
Katharina Ziegeler, Virginie Kreutzinger, Fabian Proft, Denis Poddubnyy, Kay Geert A Hermann, Torsten Diekhoff
OBJECTIVES: The aim of this investigation was to determine the prevalence of variant sacroiliac joint forms in symptomatic patients with mechanical joint disease (MJD) and axial spondyloarthritis (axSpA) compared with control patients. METHOD: A total of 973 patients were included in this cross-sectional study (95 axSpA; 61 MJD; 817 controls); clinical diagnosis, age and gender were noted. An established scoring system was used to classify joint forms on computed tomography scans of the pelvis...
April 5, 2021: Rheumatology
Heide Boeth, Robert Biesen, Jeremias Hollnagel, Sandra Herrmann, Rainald M Ehrig, Lorenzo Pelli, William R Taylor, Georg N Duda, Frank Buttgereit
OBJECTIVES: The clinical parameter "morning stiffness" is widely used to assess the status of rheumatoid arthritis (RA), but its accurate quantitative assessment in a clinical setting has not yet been successful. This lack of individual quantification limits both personalized medication and efficacy evaluation in the treatment of RA. METHODS: We have developed a novel technology to assess passive resistance of the metacarpophalangeal (MCP) III joint (stiffness) and its Passive Range of Motion (PRoM)...
April 5, 2021: Rheumatology
Yu Toyoda, Yusuke Kawamura, Akiyoshi Nakayama, Hirofumi Nakaoka, Toshihide Higashino, Seiko Shimizu, Hiroshi Ooyama, Keito Morimoto, Naohiro Uchida, Ryuichiro Shigesawa, Kenji Takeuchi, Ituro Inoue, Kimiyoshi Ichida, Hiroshi Suzuki, Nariyoshi Shinomiya, Tappei Takada, Hirotaka Matsuo
OBJECTIVES: Gout, caused by chronic elevation of serum uric acid levels, is the commonest form of inflammatory arthritis. The causative effect of common and rare variants of ATP-binding cassette transporter G2 (ABCG2/BCRP) on gout risk has been studied, but, little attention has been paid to the effect of common (rs121907892, p. W258X) and rare variants of urate transporter 1 (URAT1/SLC22A12) on gout, despite dysfunctional variants of URAT1 having been identified as pathophysiological causes of renal hypouricemia...
April 2, 2021: Rheumatology
Hélène Greigert, Morgane Mounier, Louis Arnould, Catherine Creuzot-Garcher, André Ramon, Laurent Martin, Georges Tarris, Tibor Ponnelle, Sylvain Audia, Bernard Bonnotte, Marc Maynadie, Maxime Samson
OBJECTIVES: An increased risk of hematological malignancies (HM) has been reported in giant cell arteritis (GCA) patients. Our study aimed to investigate the incidence and the type of HM occurring in GCA. METHODS: All patients with GCA and HM living in Côte D'Or (France) were identified by crossing data from the RHEMCO (Registre des Hémopathies Malignes de Côte d'Or) and those having a positive temporal artery biopsy between 1st January 2001 and 31 December 2018...
April 1, 2021: Rheumatology
Khaled Mahmoud, Ahmed S Zayat, Md Yuzaiful Md Yusof, Katherine Dutton, Lee Suan Teh, Chee-Seng Yee, David D'Cruz, Nora Ng, David Isenberg, Coziana Ciurtin, Philip G Conaghan, Paul Emery, Christopher J Edwards, Elizabeth M A Hensor, Edward M Vital
OBJECTIVE: To determine whether SLE patients with inflammatory joint symptoms and ultrasound-synovitis/tenosyovitis achieve better clinical responses to glucocorticoid compared with patients with normal scans. Secondary objectives included identification of clinical features predicting ultrasound-synovitis/tenosynovitis. METHODS: In a longitudinal muticentre study, SLE patients with physician-diagnosed inflammatory joint pain received intramuscular methylprednisolone 120 mg once...
April 1, 2021: Rheumatology
Helena Marzo-Ortega, Jon Packham, Mar Pujades-Rodriguez
No abstract text is available yet for this article.
April 1, 2021: Rheumatology
Yannick Degboé, Flavia Sunzini, Shatakshi Sood, Aline Bozec, Maria V Sokolova, Ana Zekovic, Iain B McInnes, Georg Schett, Carl S Goodyear
BACKGROUND: Psoriatic arthritis (PsA) is associated with bone erosion and inflammation-induced bone loss, which are mediated by osteoclasts and modulated by inflammatory cytokines. Apremilast (a selective phosphodiesterase 4 inhibitor) is efficacious in PsA and acts by inhibiting cytokine production. However, there are no direct data informing whether and how apremilast affects osteoclast formation in humans. METHODS: Osteoclastogenic cytokine production by activated human peripheral blood mononuclear cells (PBMCs) was measured in the presence and absence of apremilast...
March 31, 2021: Rheumatology
Ettore Silvagni, Elisabetta Chessa, Francesca Bergossi, Maria Ester D'Amico, Federica Furini, Giulio Guerrini, Alberto Cauli, Carlo Alberto Scirè, George Bertsias, Marcello Govoni, Matteo Piga, Alessandra Bortoluzzi
OBJECTIVES: Although neuropsychiatric involvement in Systemic Lupus Erythematosus (NPSLE) is one of the most complex and troubling manifestations of the disease, validated outcome instruments to be used as sensitive endpoints in controlled clinical trials are lacking. We set out a systematic literature review (SLR) to identify outcome measurement instruments and domains used to assess NPSLE. METHODS: The Preferred Reporting Items for systematic reviews and Meta-analysis (PRISMA) guidelines were used...
March 31, 2021: Rheumatology
Krystel Aouad, Philippe Gaudin, Olivier Vittecoq, Jacques Morel, Jean-Marie Berthelot, Eric Senbel, Thierry Schaeverbeke, Frédéric Lioté, René-Marc Flipo, Alexandrine Pinta, Francis Guillemin, Bruno Fautrel
OBJECTIVE: The Flare Assessment in Rheumatoid Arthritis (FLARE-RA) self-administered questionnaire aims to identify patients who had flare in the interval between 2 consultations. This study aimed to establish a threshold for FLARE-RA score to identify RA flare. METHODS: The Tocilizumab SubCutAneous (TOSCA) study evaluated the efficacy and safety of subcutaneous Tocilizumab (TCZ) to patients with active RA. Disease activity was assessed with the DAS28ESR at baseline and at week 2 (W2), W4, W12, and W24...
March 31, 2021: Rheumatology
Janne Heuvelmans, Nathan den Broeder, Geke A H van den Elsen, Alfons A den Broeder, Bart J F van den Bemt
OBJECTIVES: The aim of this study was to compare the effectiveness and tolerability between oral methotrexate (MTX) and subcutaneous MTX in a large group of rheumatoid arthritis (RA) patients in a real-life setting. METHODS: In this retrospective cohort study, adult patients with clinical diagnosis of RA who started MTX treatment (monotherapy or combined with hydroxychloroquine), either started with oral or subcutaneous MTX. The primary outcome was superiority testing of between group difference in change in DAS28CRP between baseline and 3-6 months, and subsequent non inferiority testing (NI margin 0...
March 31, 2021: Rheumatology
Akiyoshi Nakayama, Hirotaka Matsuo, Abhishek Abhishek, Kimiyoshi Ichida, Nariyoshi Shinomiya
No abstract text is available yet for this article.
March 31, 2021: Rheumatology
Tetsuro Aita, Yusuke Matsuo, Yoshie Yamada, Jun Miyata, Takashi Yoshioka
No abstract text is available yet for this article.
March 31, 2021: Rheumatology
Fetch more papers »
Fetching more papers... Fetching...
Remove bar
Read by QxMD icon Read

Save your favorite articles in one place with a free QxMD account.


Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"